Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India

AIM: Palbociclib was approved in the United States in 2015 to treat estrogen receptor–positive/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC). This study evaluated outcomes and safety in patients treated with palbociclib in Australia and India with hormone rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Loi, Sherene, Karapetis, Christos S., McCarthy, Nicole, Oakman, Catherine, Redfern, Andrew, White, Michelle, Khasraw, Mustafa, Doval, Dinesh Chandra, Gore, Vinod, Alam, Mahmood, Binko, Justin, Lu, Dongrui Ray, Kim, Sindy, Boyle, Frances
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787838/
https://www.ncbi.nlm.nih.gov/pubmed/34908235
http://dx.doi.org/10.1111/ajco.13653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787838/
https://www.ncbi.nlm.nih.gov/pubmed/34908235
http://dx.doi.org/10.1111/ajco.13653

Ejemplares similares